-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the official website of CDE showed that Jiangsu Deyuan Pharmaceutical's Enpagliflozin tablets were accepted for listing applications submitted for imitations in 4 categories
.
According to data from Mi Nei.
com, the sales of terminal Englegliflozin tablets in China's public medical institutions in 2021H1 increased by more than 200% year-on-year
.
.
According to data from Mi Nei.
com, the sales of terminal Englegliflozin tablets in China's public medical institutions in 2021H1 increased by more than 200% year-on-year
.
Enpagliflozin is a highly selective SGLT2 inhibitor, mainly used to improve blood glucose control in patients with type 2 diabetes
.
It was jointly developed by Eli Lilly and Boehringer Ingelheim.
In May 2014, the European Commission approved the listing for the first time.
In August of the same year, it was approved by the US FDA for listing.
In September 2017, it was listed in China
.
.
It was jointly developed by Eli Lilly and Boehringer Ingelheim.
In May 2014, the European Commission approved the listing for the first time.
In August of the same year, it was approved by the US FDA for listing.
In September 2017, it was listed in China
.
Sales of terminal Englegliflozin tablets in public medical institutions in China in recent years (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
According to data from Menet.
com, in 2020, the sales of terminal enpagliflozin tablets in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (Chinese public medical institutions) will exceed 100 million yuan, with a year-on-year growth in 2021H1.
Ringer Ingelheim has the largest market share, exceeding 90%
.
com, in 2020, the sales of terminal enpagliflozin tablets in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (Chinese public medical institutions) will exceed 100 million yuan, with a year-on-year growth in 2021H1.
Ringer Ingelheim has the largest market share, exceeding 90%
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
There are 6 manufacturers of Engligliflozin tablets.
After Jiangsu Haosen Pharmaceutical won the first imitation in 2020, 5 domestic companies including Sichuan Kelun Pharmaceutical and Chia Tai Tianqing Pharmaceutical Group have applied for imitation 4 types of production.
Approved and deemed to have been reviewed
.
It is worth mentioning that this product is the fourth batch of collectively sourced varieties
.
At present, 6 companies including Lepu Pharmaceutical, Chengdu Better Pharmaceutical, and Yangtze River Pharmaceutical Group Beijing Haiyan Pharmaceutical|Jiangsu Coast Pharmaceutical have submitted listing applications and are under review and approval
.
After Jiangsu Haosen Pharmaceutical won the first imitation in 2020, 5 domestic companies including Sichuan Kelun Pharmaceutical and Chia Tai Tianqing Pharmaceutical Group have applied for imitation 4 types of production.
Approved and deemed to have been reviewed
.
It is worth mentioning that this product is the fourth batch of collectively sourced varieties
.
At present, 6 companies including Lepu Pharmaceutical, Chengdu Better Pharmaceutical, and Yangtze River Pharmaceutical Group Beijing Haiyan Pharmaceutical|Jiangsu Coast Pharmaceutical have submitted listing applications and are under review and approval
.
Source: CDE official website, Minet database
A few days ago, the official website of CDE showed that Jiangsu Deyuan Pharmaceutical's Enpagliflozin tablets were accepted for listing applications submitted for imitations in 4 categories
.
According to data from Mi Nei.
com, the sales of terminal Englegliflozin tablets in China's public medical institutions in 2021H1 increased by more than 200% year-on-year
.
.
According to data from Mi Nei.
com, the sales of terminal Englegliflozin tablets in China's public medical institutions in 2021H1 increased by more than 200% year-on-year
.
Enpagliflozin is a highly selective SGLT2 inhibitor, mainly used to improve blood glucose control in patients with type 2 diabetes
.
It was jointly developed by Eli Lilly and Boehringer Ingelheim.
In May 2014, the European Commission approved the listing for the first time.
In August of the same year, it was approved by the US FDA for listing.
In September 2017, it was listed in China
.
.
It was jointly developed by Eli Lilly and Boehringer Ingelheim.
In May 2014, the European Commission approved the listing for the first time.
In August of the same year, it was approved by the US FDA for listing.
In September 2017, it was listed in China
.
Sales of terminal Englegliflozin tablets in public medical institutions in China in recent years (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
According to data from Menet.
com, in 2020, the sales of terminal enpagliflozin tablets in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (Chinese public medical institutions) will exceed 100 million yuan, with a year-on-year growth in 2021H1.
Ringer Ingelheim has the largest market share, exceeding 90%
.
com, in 2020, the sales of terminal enpagliflozin tablets in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (Chinese public medical institutions) will exceed 100 million yuan, with a year-on-year growth in 2021H1.
Ringer Ingelheim has the largest market share, exceeding 90%
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
There are 6 manufacturers of Engligliflozin tablets.
After Jiangsu Haosen Pharmaceutical won the first imitation in 2020, 5 domestic companies including Sichuan Kelun Pharmaceutical and Chia Tai Tianqing Pharmaceutical Group have applied for imitation 4 types of production.
Approved and deemed to have been reviewed
.
It is worth mentioning that this product is the fourth batch of collectively sourced varieties
.
At present, 6 companies including Lepu Pharmaceutical, Chengdu Better Pharmaceutical, and Yangtze River Pharmaceutical Group Beijing Haiyan Pharmaceutical|Jiangsu Coast Pharmaceutical have submitted listing applications and are under review and approval
.
After Jiangsu Haosen Pharmaceutical won the first imitation in 2020, 5 domestic companies including Sichuan Kelun Pharmaceutical and Chia Tai Tianqing Pharmaceutical Group have applied for imitation 4 types of production.
Approved and deemed to have been reviewed
.
It is worth mentioning that this product is the fourth batch of collectively sourced varieties
.
At present, 6 companies including Lepu Pharmaceutical, Chengdu Better Pharmaceutical, and Yangtze River Pharmaceutical Group Beijing Haiyan Pharmaceutical|Jiangsu Coast Pharmaceutical have submitted listing applications and are under review and approval
.
Source: CDE official website, Minet database
A few days ago, the official website of CDE showed that Jiangsu Deyuan Pharmaceutical's Enpagliflozin tablets were accepted for listing applications submitted for imitations in 4 categories
.
According to data from Mi Nei.
com, the sales of terminal Englegliflozin tablets in China's public medical institutions in 2021H1 increased by more than 200% year-on-year
.
.
According to data from Mi Nei.
com, the sales of terminal Englegliflozin tablets in China's public medical institutions in 2021H1 increased by more than 200% year-on-year
.
Enpagliflozin is a highly selective SGLT2 inhibitor, mainly used to improve blood glucose control in patients with type 2 diabetes
.
It was jointly developed by Eli Lilly and Boehringer Ingelheim.
In May 2014, the European Commission approved the listing for the first time.
In August of the same year, it was approved by the US FDA for listing.
In September 2017, it was listed in China
.
.
It was jointly developed by Eli Lilly and Boehringer Ingelheim.
In May 2014, the European Commission approved the listing for the first time.
In August of the same year, it was approved by the US FDA for listing.
In September 2017, it was listed in China
.
Sales of terminal Englegliflozin tablets in public medical institutions in China in recent years (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
According to data from Menet.
com, in 2020, the sales of terminal enpagliflozin tablets in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (Chinese public medical institutions) will exceed 100 million yuan, with a year-on-year growth in 2021H1.
Ringer Ingelheim has the largest market share, exceeding 90%
.
Hospital hospital hospitalcom, in 2020, the sales of terminal enpagliflozin tablets in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (Chinese public medical institutions) will exceed 100 million yuan, with a year-on-year growth in 2021H1.
Ringer Ingelheim has the largest market share, exceeding 90%
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
There are 6 manufacturers of Engligliflozin tablets.
After Jiangsu Haosen Pharmaceutical won the first imitation in 2020, 5 domestic companies including Sichuan Kelun Pharmaceutical and Chia Tai Tianqing Pharmaceutical Group have applied for imitation 4 types of production.
Approved and deemed to have been reviewed
.
It is worth mentioning that this product is the fourth batch of collectively sourced varieties
.
At present, 6 companies including Lepu Pharmaceutical, Chengdu Better Pharmaceutical, and Yangtze River Pharmaceutical Group Beijing Haiyan Pharmaceutical|Jiangsu Coast Pharmaceutical have submitted listing applications and are under review and approval
.
Enterprise business enterpriseAfter Jiangsu Haosen Pharmaceutical won the first imitation in 2020, 5 domestic companies including Sichuan Kelun Pharmaceutical and Chia Tai Tianqing Pharmaceutical Group have applied for imitation 4 types of production.
Approved and deemed to have been reviewed
.
It is worth mentioning that this product is the fourth batch of collectively sourced varieties
.
At present, 6 companies including Lepu Pharmaceutical, Chengdu Better Pharmaceutical, and Yangtze River Pharmaceutical Group Beijing Haiyan Pharmaceutical|Jiangsu Coast Pharmaceutical have submitted listing applications and are under review and approval
.
Source: CDE official website, Minet database
